Cargando…

Revisiting Experimental Models of Diabetic Nephropathy

Diabetes prevalence is constantly increasing and, nowadays, it affects more than 350 million people worldwide. Therefore, the prevalence of diabetic nephropathy (DN) has also increased, becoming the main cause of end-stage renal disease (ESRD) in the developed world. DN is characterized by albuminur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giralt-López, Anna, Molina-Van den Bosch, Mireia, Vergara, Ander, García-Carro, Clara, Seron, Daniel, Jacobs-Cachá, Conxita, Soler, Maria José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278948/ https://www.ncbi.nlm.nih.gov/pubmed/32438732 http://dx.doi.org/10.3390/ijms21103587

Ejemplares similares

Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model
por: Vergara, Ander, et al.
Publicado: (2021)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
por: García-Carro, Clara, et al.
Publicado: (2019)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Matrix Metalloproteinases in Diabetic Kidney Disease
por: Garcia-Fernandez, Nuria, et al.
Publicado: (2020)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2021)

The COVID-19 pandemic: progress in nephrology
por: Soler, María José, et al.
Publicado: (2021)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease
por: Román, Juan León, et al.
Publicado: (2021)

Safety of Obtaining an Extra Biobank Kidney Biopsy Core
por: Bermejo, Sheila, et al.
Publicado: (2022)

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2022)

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
por: García-Carro, Clara, et al.
Publicado: (2021)

Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2023)

Glomeruloesclerosis focal y segmentaria asociada a infección por COVID-19
por: LeónRomán, Juan, et al.
Publicado: (2021)

Focal and segmental glomerulosclerosis associated with COVID-19 infection()
por: Román, Juan León, et al.
Publicado: (2021)

New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy
por: Soler, María José, et al.
Publicado: (2012)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
por: García-Carro, Clara, et al.
Publicado: (2021)

Kaliopenic nephropathy revisited
por: Elitok, Saban, et al.
Publicado: (2016)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

IgM nephropathy revisited
por: Mubarak, Muhammed, et al.
Publicado: (2012)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?
por: León-Román, Juan, et al.
Publicado: (2022)

Irbesartan in experimental diabetic nephropathy
por: Mahajan, Rajiv, et al.
Publicado: (2010)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19
por: Vergara, Ander, et al.
Publicado: (2021)

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP()
por: Zúñiga, José, et al.
Publicado: (2021)

Infección por SARS-CoV-2 en pacientes con enfermedad renal crónica en hemodiálisis. Evolución de la PCR de SARS-CoV-2
por: Zúñiga, José, et al.
Publicado: (2021)

Are glomerular patients treated with immunosupressed drugs more protected against sever SARS-Covid -2?
por: Agraz-Pamplona, Irene, et al.
Publicado: (2020)

Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival
por: García-Carro, Clara, et al.
Publicado: (2023)

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience
por: Oleas, Diana, et al.
Publicado: (2020)

Experimental Models of Type-2 Diabetic Nephropathy
por: Tomino, Yasuhiko, et al.
Publicado: (2012)

Biochemical effects of irbesartan in experimental diabetic nephropathy
por: Vaishya, Richa, et al.
Publicado: (2009)

Chinese medicines in the treatment of experimental diabetic nephropathy
por: Liu, Jing-Yi, et al.
Publicado: (2016)

Novel Role of Parathyroid Hormone-Related Protein in the Pathophysiology of the Diabetic Kidney: Evidence from Experimental and Human Diabetic Nephropathy
por: Romero, Montserrat, et al.
Publicado: (2013)

‘Experimental pregnancy’ revisited
por: Lyerly, Anne Drapkin
Publicado: (2022)

Analysis of the Influence of Diabetic Nephropathy in Patients with Diabetic Foot Osteomyelitis
por: García-Álvarez, Yolanda, et al.
Publicado: (2023)

Experimental model of nephropathy associated with diabetes mellitus in mice
por: Silva, Pâmela Henrique, et al.
Publicado: (2023)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_71bp5cjhrl6c9vg783diomnqsu